Avalo Therapeutics, Inc.
AVTX · Price history
Price at last available close
$7.12
−$8.46 (-54.30%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Avalo Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis.
How they make money
Avalo Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of therapeutic candidates, specifically its lead asset abdakibart (AVTX-009), to treat immune dysregulation and inflammatory diseases, with the goal of eventually commercializing these assets or entering into licensing agreements.
Products & services
The company's primary product candidate is abdakibart (AVTX-009), a high-affinity, humanized IgG monoclonal antibody designed to inhibit IL-1β and block downstream inflammatory pathways, currently in clinical development.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- Eli Lilly and Company — Avalo holds rights to abdakibart (AVTX-009) through a license agreement originally established with Eli Lilly and Company.Source
- Leap Therapeutics, Inc. — Avalo acquired rights to abdakibart (AVTX-009) through its acquisition of AlmataBio, which had previously purchased rights to the compound from Leap Therapeutics.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
14
Poor
Financial Strength
11
Business Quality / Moat
0
Management
40
Growth Quality
18
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
26
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
31/100
Building Historical Record
Model Score 31/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Material dilution — approximately 292.1% share-count growth
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for AVTX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AVTX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can AVTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is AVTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for AVTX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AVTX's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Opportunity Score
26
Market Cap
$381.8M
P/E Ratio
-3.2
EPS
$-4.74
52-Week High
$24.27
52-Week Low
$12.41
Beta
0.79
Analyst Target
$46.50
Shares Outstanding
52.6M
Total Revenue
$59K
Total Debt
$242K
Dividend
No current dividend
Liquidation Value / Share
$8.54
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AVTX
Detected from reported data — verify before acting.Material dilution — approximately 292.1% share-count growth
Shares outstanding increased approximately 292.1% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 25.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCommunity Sentiment
0 active · 0 total callsNo personal call yet on AVTX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Clinical-stage pipeline focused on high-affinity monoclonal antibodies.
- +Sufficient cash runway to finance operations into 2028.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of net losses and expectation of continued future losses.
- −Dependence on the successful development and regulatory approval of lead product candidate abdakibart.
- −Shares outstanding increased approximately 292.1% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 25.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
17
Sep 9, 2026
Change
Unchanged
Current Score
17
Oct 1, 2026
Category Changes
AVTX score was unchanged.
Positive Contributors
- + Asset improved by 4.3 points
Projected Score
Projected Score
19
Projected Change
+2.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$7.12
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -86.6%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59K | $59K | $441K | $1.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | -$16.6M | $0.00 | -$366K | $1.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $16.6M | $59K | $807K | $640K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $64.4M | $50.1M | $52.1M | $13.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $27.0M | $22.9M | $17.2M | $10.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $108.0M | $73.0M | $69.3M | $28.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$100.0M | -$77.8M | -$34.8M | -$23.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$91.4M | -$72.9M | -$68.5M | -$27.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $3.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$100.2M | -$78.1M | -$35.0M | -$31.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $171K | $165K | $114K | $14K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$100.3M | -$78.3M | -$35.1M | -$31.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.48 | $-5.84 | $-4.32 | $-113.58 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 43.60M | 13.40M | 8.13M | 278K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 43.60M | 13.40M | 10.78M | 278K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.83
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-64.4%
Cash Change
+101.9%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 56.8%. Cash increased 101.9%. Total debt declined 64.4%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Rumor Mill · AVTX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial